WARNING: This post contains mention of sexual abuse
On May 12th, 2022, Canadian Drug Policy Coalition (CDPC) posted a statement. The CDPC statement, removed from the website drugpolicy.ca on May 20th, addressed concerns involving an incident of sexual abuse that came to light in 2018, within a clinical trial conducted by the Multidisciplinary Association for Psychedelic Studies in the United States (MAPS) and also implicated MAPS Canada. The CDPC statement suggested that there were reports that MAPS “ignored, minimized, suppressed and used a participant’s formal account of sexual assault to coerce her into a position of extreme social and economic precarity”. CDPC had not independently verified any such reports. CDPC has retracted the CDPC statement. We apologize for any errors within the original statement. CDPC maintains its unequivocal support for victims of clinical malpractice engaged in psychedelic therapeutic trials.
We would like to make explicit that the May 12th CDPC statement and this statement do not necessarily reflect the views of the over 50 organizations that are members of the Canadian Drug Policy Coalition.
